Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 May 26;24(23):3847-52.
doi: 10.1038/sj.onc.1208518.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

Affiliations

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

Gyorgy Petrovics et al. Oncogene. .

Erratum in

  • Oncogene. 2007 Oct 11;26(46):6684. Furasato, Bungo [corrected to Furusato, Bungo]

Abstract

Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen (54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.

PubMed Disclaimer

Similar articles

Cited by

  • TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.
    Demichelis F, Rubin MA. Demichelis F, et al. J Clin Pathol. 2007 Nov;60(11):1185-6. doi: 10.1136/jcp.2007.046557. J Clin Pathol. 2007. PMID: 17965219 Free PMC article. Review.
  • Advances in Prostate Cancer Biomarkers and Probes.
    Li K, Wang Q, Tang X, Akakuru OU, Li R, Wang Y, Zhang R, Jiang Z, Yang Z. Li K, et al. Cyborg Bionic Syst. 2024 Jun 27;5:0129. doi: 10.34133/cbsystems.0129. eCollection 2024. Cyborg Bionic Syst. 2024. PMID: 40353136 Free PMC article. Review.
  • Precision medicine applications in prostate cancer.
    McCrea EM, Lee DK, Sissung TM, Figg WD. McCrea EM, et al. Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29977347 Free PMC article. Review.
  • Clinical Applications of Molecular Biomarkers in Prostate Cancer.
    Couñago F, López-Campos F, Díaz-Gavela AA, Almagro E, Fenández-Pascual E, Henríquez I, Lozano R, Linares Espinós E, Gómez-Iturriaga A, de Velasco G, Quintana Franco LM, Rodríguez-Melcón I, López-Torrecilla J, Spratt DE, Guerrero LL, Martínez-Salamanca JI, Del Cerro E. Couñago F, et al. Cancers (Basel). 2020 Jun 12;12(6):1550. doi: 10.3390/cancers12061550. Cancers (Basel). 2020. PMID: 32545454 Free PMC article. Review.
  • Clinical Biofluid Assays for Prostate Cancer.
    Borbiev T, Kohaar I, Petrovics G. Borbiev T, et al. Cancers (Basel). 2023 Dec 28;16(1):165. doi: 10.3390/cancers16010165. Cancers (Basel). 2023. PMID: 38201592 Free PMC article. Review.

Publication types

MeSH terms